Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "By expanding the miR-AGE study to Brazil, currently the pandemic's most active country, we hope to be able to provide an efficient therapeutic option for the treatment of high-risk COVID-19 patients. We are also advancing the approval process in additional Latin American countries that are heavily affected by the rapid expansion of the pandemic. In parallel, patient recruitment is progressing according to our expectations for our ongoing clinical trials with ABX464, i.e. the Phase 2b in ulcerative colitis and Phase 2a in rheumatoid arthritis, as well as the US Phase 1/2 trial with ABX196 to treat hepatocellular carcinoma."Prof. Jorge Kalil, M.D., Ph.D., Head of Immunology at the University Hospital in Sao Paulo and miR-AGE overall study coordinator in Brazil, added: "We are eager to start the miR-AGE trial in Brazil and to test this innovative and promising drug candidate for the benefit of all countries and patients affected by the COVID-19 pandemic, which is still globally present. We hope to see a positive effect from the early treatment with ABX464 in reducing the severity of the disease by inhibiting viral replication, preventing hyper-inflammation and thus the potential deadly acute respiratory distress syndrome and also by limiting potential long-term lung injury in patients."Philippe Pouletty, M.D., Chairman of the Board of Abivax, said: "We are proud that Abivax's ABX464 was selected by the French government as a promising drug candidate for treatment of COVID-19. We wish to thank Bpifrance, the Secrétariat Général pour l'Investissement (SGPI) and the French government for their backing and support of Abivax. At the same time, while we are confident that ABX464 may have a positive impact by reducing the severity of COVID-19 sequelae, we remain prudent on expectations for the miR-AGE trial given the complexities surrounding treatment of COVID-19 disease. Progressing ABX464 development in chronic inflammatory diseases remains Abivax's corporate priority."
With regards to the financial situation of the Company, the final agreements with Bpifrance, the investment bank of the French state, have been signed following the French government's selection of six development projects for a potent COVID-19 treatment. These projects will be financed with a total of 78m EUR by the French state, of which Abivax will receive 36m EUR in non-dilutive funding for its 1,034-patient ABX464 Phase 2b/3 COVID-19 (miR-AGE) trial, manufacturing scale-up, as well as additional development costs related to other ABX464 studies and the potential filing of ABX464 Marketing Authorization Applications (MAA). Abivax recently also announced a further 5m EUR non-dilutive financing from Société Générale in the form of a loan guaranteed by the French state (PGE - Prêts Garantis par l'Etat).Didier Blondel, Chief Financial Officer of Abivax, said: "With the official signing of the final contracts with Bpifrance and the loan recently granted by Société Générale, Abivax's cash resources will fully finance the corporate objectives and current development plans until early 2021. We currently plan to continue to focus on sourcing additional non-dilutive financing options for the longer term." The Company also announces today that it held its annual ordinary and extraordinary general meetings on June 19, 2020 behind closed doors, under the chairmanship of Dr. Philippe Pouletty, Chairman of the Board of Directors and without the physical presence of its shareholders due to COVID-19 social distancing practices.
All resolutions presented by the Board of Directors were adopted, including the compensation policy applicable to the Chief Executive Officer and the directors. Details of the voting results on all resolutions will be available on the company website.
About Abivax Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Abivax Communications Regina Jehleregina.firstname.lastname@example.org +33 6 24 50 69 63 InvestorsLifeSci Advisors Chris Maggoschris@lifesciadvisors.com +41 79 367 6254 Press Relations & Investors EuropeMC Services AG Anne Henneckeanne.email@example.com +49 211 529 252 22 Public Relations FranceActifin Ghislaine Gasparettoggasparetto@actifin.fr +33 6 21 10 49 24 Public Relations FranceDGM Conseil Thomas Roborel de Climensthomasdeclimens@dgm-conseil.fr +33 6 14 50 15 84 Public Relations USA Rooney Partners LLC Marion Janicmjanic@rooneyco.com +1 212 223 4017
This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document de Référence). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
22.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de